Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 464

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 464
---
. Zakes, Longevity’s Chief Executive Officer, President and director is also Chief Executive Officer and a director and stockholder of Cerevast.

Promissory Notes

Longevity has received debt financing from FutureTech Partners evidenced by promissory notes, as described below, issued to FutureTech Partners in the aggregate principal amount of $7.2 million. The notes are non-interest-bearing and the principal amount of the notes is payable in full on the earlier of (i) the six-month anniversary of the issuance date of the note or (ii) the consummation of the Business Combination. Longevity may prepay the notes in its sole discretion without premium or penalty. The notes outstanding to date have been assigned by FutureTech Partners to its affiliate, FutureTech Capital LLC (“FutureTech Capital”), and all notes issued to FutureTech Partners in the future will also be assigned to FutureTech Capital. Prior to the closing of the Business Combination, the notes will be converted to shares of Longevity calculated as follows: (i) in exchange for the first $6.215 million of principal amount of notes outstanding, that number of shares of Longevity Common Stock equal to 20% of the total number of shares of Longevity Common Stock to be outstanding immediately prior to LBI Effective Time, plus (ii) in exchange for each additional $750,000 of principal amount of promissory notes outstanding, that number of shares of Longevity Common Stock equal to an additional 1% of Longevity common stock outstanding.

| 258 |

Yuquan Wang, a manager of FutureTech Partners, also serves as a board member and a 71.83% stockholder (indirectly through affiliates) of Cerevast.

Policies and Procedures for Related Person Transactions

Upon the Closing, Longevity will adopt a written related person transaction policy that sets forth the following policies and procedures for the review and approval or ratification of related person transactions.

A “Related Person Transaction” is a transaction, arrangement or relationship in which Longevity or any of its subsidiaries was, is or will be a participant, the amount of which involved exceeds $120,000, and in which any related person had, has or will have a direct or indirect material interest. A “Related Person” means:

| ● | any                                                                                                                     
 person who is, or at any time during the applicable period was, one of Combined Entity’s officers or one of Longevity’s 
 directors;                                                                                                              |

| ● | any                                                                                 
 person who is known